CYTOKINE THERAPY OF METASTATIC RENAL-CELL CARCINOMA

Cytokine therapy of metastatic renal cell carcinoma reveals a remissio n rate of about 25% regarding to the different patients selection crit erias, i.e. age, performance status, site of metastasis, tumour load. Remission is not correlated to patient's survival. Adjuvant or neoadju vant immunotherapy is not a treatment option. Nephrectomy has no influ ence on distant metastases and should be limited to symptomatic primar y tumours. In conclusion, cytokine therapy is not a standard treatment . Its value has to be evaluated in randomized trials.